The present studies present first time evidence for the activation of anaplastic lymphoma kinase (ALK) pathway activation in pre-clinical models of IBC, that was consistent with detection of increased gains in copy numbers of ALK, low level ALK gene amplification, ALK gene expression or more rarely, the presence of EML4-ALK translocation in IBC breast tumors. This evidence concerns the gene ALK and inflammatory breast carcinoma.